G
Greenland Mines Ltd
GRMLCIK 0001907223NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)FY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-10.55M
Total Assets
$9.59M
Equity
$9.46M
Shares Out
121.24M
Op. Cash Flow
$-5.89M
Business
Klotho Neurosciences, Inc. develops medicines for chronic diseases with a strategic focus on gene and cell therapy using the Klotho gene and a licensed biosimilar/generic drug portfolio. Its main products and services include proprietary gene therapy candidates (e.g., KLTO-101 and KLTO-202 leveraging the s-KL isoform), biosimilar monoclonal antibodies and off-patent small-molecule generics, and development of isoform‑specific Klotho assays. The company operates distinct cell/gene therapy and biosimilar/generic programs supported by licensing and sponsored research. It targets regulatory approvals and commercial markets in the U.S., Canada, Europe, China and other viable jurisdictions, and distributes certain acquired oncology drugs in European markets.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Professional fees | 3 | 3 | 600,776 | — | |
| General and administrative | 2 | 129,418 | 30,546 | 533,992 | |
| Research and development | 634,187 | — | — | — | |
| Share-based compensation | 2 | 3 | — | — | |
| Total operating expenses | 7 | 6 | 631,322 | — | |
| Net operating loss | −7 | −6 | −631,322 | −657,018 | |
| Interest expense | −2 | −356,603 | −76,214 | — | |
| Change in fair value of warrant liability | −28,514 | −1,961 | — | 555,917 | |
| Settlement expense | 1 | — | — | — | |
| Other income (expense) | 115,066 | −251,572 | 78 | — | |
| Total other income (expense) | −3 | −610,136 | −76,136 | — | |
| Net loss before income taxes | −11 | −6 | −707,458 | 2 | |
| Income taxes | — | — | — | −322,025 | |
| Net loss | −11 | −6 | −707,458 | 1 | |
| Net loss per share: Basic (in Dollars per share) | −0.22 | −0.32 | −0.05 | — | |
| Net loss per share: Diluted (in Dollars per share) | −0.22 | −0.32 | −0.05 | — | |
| Weighted average common shares outstanding (in Shares) | 48 | 19 | 15 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-08-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 100,000 | 2,808 | 340,962 | — | |
| Prepaid expenses | 117,071 | 94,070 | 3,840 | 99,196 | — | |
| Total current assets | 7 | 157,811 | 6,648 | 440,158 | — | |
| Licenses | 2 | 2 | 2 | — | — | |
| Patents | 48,420 | 48,420 | 48,420 | — | — | |
| Total other assets | 2 | 2 | 2 | — | — | |
| Total assets | 10 | 2 | 2 | 118 | — | |
| Accounts payable | 44,607 | 63,686 | 151,259 | — | — | |
| Accrued expenses | 32,157 | 912,095 | 2,460 | 140,370 | — | |
| Notes payable | — | 240,753 | 1 | — | 1 | |
| Total current liabilities | 76,764 | 1 | 2 | 506,241 | — | |
| Warrant liability | 53,000 | 24,486 | — | 31,800 | — | |
| Total liabilities | 129,764 | 1 | 2 | 5 | — | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, par value $0.0001, 100,000,000 shares authorized; 0 issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Common stock, par value $0.0001, 1,000,000,000 shares authorized; 72,536,722 and 27,080,915 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 7,254 | 2,708 | 1,513 | 340 | — | |
| Common stock to be issued | 516,000 | — | — | — | — | |
| Additional paid-in capital | 30 | 12 | 4 | — | — | |
| Accumulated deficit | −21 | −11 | −4 | −4 | — | |
| Total stockholders equity | 9 | 1 | −442,701 | −4 | — | |
| Total liabilities and stockholders equity | 10 | 2 | 2 | 118 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Commitment fee | — | 250,000 | — | — | |
| Impairment on intangible assets | — | 10,000 | — | — | |
| Interest expense | 2 | 141,753 | — | — | |
| Settlement on note payable | 1 | — | — | — | |
| Conversion of debt to equity | 448,802 | — | — | — | |
| Consulting fees | 516,000 | — | — | — | |
| Prepaid expenses | −23,001 | −90,230 | −173 | −99,196 | |
| Accounts payable | −19,079 | −187,573 | 103,997 | — | |
| Accrued expenses | −879,938 | 1 | −2,282 | 140,370 | |
| Tax payable | — | −568,111 | — | — | |
| Related party payable | −31,000 | −128,000 | — | — | |
| Other Liabilities | — | 60,022 | — | — | |
| Net cash used in operating activities | −6 | −3 | −446,916 | −493,043 | |
| Acquisition of drug license | — | −123,497 | −13,888 | −116 | |
| Net cash used in investing activities | — | −123,497 | 23,852 | −116 | |
| Proceeds from convertible promissory note, net of issuance cost | 2 | 2 | — | — | |
| Proceeds from sales of stocks and warrants, net | 11 | 175,000 | — | — | |
| Proceeds from stock subscriptions | 500,000 | — | — | — | |
| Proceeds from sale of preferred B shares | 500,000 | — | — | — | |
| Payments on notes payable | −3 | — | — | −200,000 | |
| Payments for deferred financing costs | −25,000 | — | — | — | |
| Proceeds from FPA settlement | 140,572 | — | — | — | |
| Payments on financed director and officer insurance | −40,225 | — | — | — | |
| Proceeds from At-the-Market sales of common shares | 1 | — | 100,000 | 25,000 | |
| Proceeds from related party loans | — | 100,000 | — | 200,000 | |
| Proceeds from shareholders | — | 120,000 | — | — | |
| Payments to shareholders | — | −120,000 | — | — | |
| Merger proceeds net of transaction cost | — | 778,942 | — | — | |
| Net cash provided by financing activities | 13 | 3 | 350,000 | 117 | |
| NET CHANGE IN CASH | 7 | 60,933 | −73,064 | 336,010 | |
| Note payable settled with issuance of common stock | 1 | 5 | — | — | |
| Interest payable settled with issuance of common stock | 57,641 | 60,022 | — | — | |
| Reversal of OID | 681,506 | — | — | — | |
| Repurchase of warrants | 679,577 | — | — | — | |
| Issuance of warrants | −679,577 | — | — | — | |
| Discretionary non-cash payment to creditor with issuance of common stock | 202 | 154,830 | — | — | |
| Conversion of Preferred B Shares to common stock | −625 | — | — | — | |
| Deemed dividend - warrant modification | −2 | — | — | — | |
| Non-cash equity payment for inducement fee on note payable | — | 978,000 | — | — | |
| Non-cash directors and officers insurance | — | 154,500 | — | — | |
| Non-cash PIPE Funds used for merger transaction close | — | 3 | — | — | |
| Commitment fee paid in stock | — | 250,000 | — | — | |
| Assumed income tax payable from merger | — | 568,111 | — | — | |
| Assumed warrant liability from merger | — | 22,525 | — | — | |
| Warrant conversion | — | 96,200 | — | — | |
| Interest Paid | 79,153 | 2,460 | 78,496 | — | |
| Taxes Paid | — | 551,593 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro